Table 1

Study characteristics and quality evaluation of each selected study

CharacteristicLee et al. (14)Woelnerhanssen et al. (15)Helmiö et al. (16)Kehagias et al. (17)Ramón et al. (18)
Jadad score55454
 Double blind22121
 Randomization22222
 Lost to follow-up11111
CountryTaiwan, ChinaSwitzerlandFinlandGreeceSpain
Clinical trial registrationNCT00540462NCT00356213NRNRNR
Study periodSept. 1, 2007 to June 30, 2008NRMarch 2008 to June 2010January 2005 to February 2007April 2007 to March 2008
Publication year20112011201220112012
No. patients60232386015
 LRYGB3012117307
 LSG3011121308
Follow-up, mo121213612
BMI30.3 (25–34)> 40, with comorbidity44.6 (35–66)< 50> 40 or BMI > 35 with comorbidity
ConditionT2DMNondiabetic morbidly obeseMorbid obesityNonsuperobeseNonsuperobese
Age, yr45 (34–58)< 6049 (23–67)NR18–60
Deaths0000NR
  • BMI = body mass index; LRYGB = laparoscopic Roux-en-Y gastric bypass; LSG = laparoscopic sleeve gastrectomy; NR = not reported; T2DM = type 2 diabetes mellitus.